Pharma BD Deal Intelligence
Post-Humira immunology backfill with a Phase 3 IL-13 antibody
Full analysis, sources & comparables →AbbVie to acquire Apogee Therapeutics for ~$10.9 billion at $135.11 per share in cash; lead asset zumilokibart (APG777), an anti-IL-13 mAb for atopic…
AbbVie Form 8-K announcing definitive agreement to acquire Apogee Therapeutics.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction at $135.11 per share, deepening AbbVie's immunology portfolio. Apogee's lead candidate zumilokibart (APG777) is a subcutaneous, half-life-extended anti-IL-13 monoclonal antibody in development for atopic dermatitis and asthma, with Phase 2 data showing ~two-thirds of treated patients achieving significant skin clearance at 16 weeks on quarterly or twice-yearly dosing. It is the year's second-largest biotech acquisition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Apogee Therapeutics, Inc. (this deal) | 2026 | $10.9B | 72 |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
| AbbVie Inc. / MedinCell S.A. | 2024 | $1.9B | 61 |
← Browse all deals · How we score deals
More: 2026 deals · AbbVie Inc. deals · Immunology deals